Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Stock Information for Kezar Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kezar Life Sciences Inc.

Kezar Life Sciences Reports Third Quarter 2025 Financial Results
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2025
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.